Eradication of melanoma <i>in vitro</i> and <i>in vivo</i> via targeting with a Killer-Red-containing telomerase-dependent adenovirus

Takehara, Kiyoto; Yano, Shuya; Tazawa, Hiroshi; Kishimoto, Hiroyuki; Narii, Nobuhiro; Mizuguchi, Hiroyuki; Urata, Yasuo; Kagawa, Shunsuke; Fujiwara, Toshiyoshi; Hoffman, Robert M.

doi:10.1080/15384101.2016.1249548

Cited by 9 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their studies have demonstrated that intratumor injection of TelomeKiller can inhibit the growth of non-small cell lung cancer and eliminate metastasis after the illumination of yellow-orange light (590 nm, 180 mW/cm 2 , 60 min) [ 62 ]. This recombinant vector is also efficient in eliminating human malignant melanoma after light stimulation (589 nm, 300 mW/cm 2 , 45 min) [ 63 ]. Moreover, a müller cells-specific adeno-associated virus vector expressed KillerRed in the vitreous of mice has been used to explore the changes in the structure and function of the retina after light stimulation (540–580 nm, 1000 lux, 60 min).…”

Section: Applications Of Killerred As An Endogenous Photosensitizermentioning

confidence: 99%

Advances in the Genetically Engineered KillerRed for Photodynamic Therapy Applications

Liu

Wang

Yang

et al. 2021

IJMS

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a clinical treatment for cancer or non-neoplastic diseases, and the photosensitizers (PSs) are crucial for PDT efficiency. The commonly used chemical PSs, generally produce ROS through the type II reaction that highly relies on the local oxygen concentration. However, the hypoxic tumor microenvironment and unavoidable dark toxicity of PSs greatly restrain the wide application of PDT. The genetically encoded PSs, unlike chemical PSs, can be modified using genetic engineering techniques and targeted to unique cellular compartments, even within a single cell. KillerRed, as a dimeric red fluorescent protein, can be activated by visible light or upconversion luminescence to execute the Type I reaction of PDT, which does not need too much oxygen and surely attract the researchers’ focus. In particular, nanotechnology provides new opportunities for various modifications of KillerRed and versatile delivery strategies. This review more comprehensively outlines the applications of KillerRed, highlighting the fascinating features of KillerRed genes and proteins in the photodynamic systems. Furthermore, the advantages and defects of KillerRed are also discussed, either alone or in combination with other therapies. These overviews may facilitate understanding KillerRed progress in PDT and suggest some emerging potentials to circumvent challenges to improve the efficiency and accuracy of PDT.

show abstract

Section: Applications Of Killerred As An Endogenous Photosensitizermentioning

confidence: 99%

Advances in the Genetically Engineered KillerRed for Photodynamic Therapy Applications

Liu

Wang

Yang

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“… 43 In contrast, PDT is a minimally invasive antitumor technique for inducing tumor‐specific cytotoxicity through the induction of photosensitizer‐mediated generation of ROS upon light irradiation. 44 , 45 For the application of hTERT promoter‐driven replicative viruses to PDT, we generated a telomerase‐specific replicative photodynamic viral agent known as TelomeKiller, which harbors the KillerRed expression cassette in the E3 region, enabling elimination of tumor cells through KillerRed‐mediated generation of ROS upon green‐light irradiation 46 , 47 (Figure 2 and Table 1 ). Thus, hTERT promoter‐driven viral vectors are useful tools for detecting and eradicating telomerase‐positive tumor cells.…”

Section: Tumor‐specific Promoter‐dependent Fluorescence Labelingmentioning

confidence: 99%

Tumor‐targeted fluorescence labeling systems for cancer diagnosis and treatment

et al. 2022

Self Cite

View full text Add to dashboard Cite

Conventional imaging techniques are available for clinical identification of tumor sites. However, detecting metastatic tumor cells that are spreading from primary tumor sites using conventional imaging techniques remains difficult. In contrast, fluorescence-How to cite this article: Tazawa H, Shigeyasu K, Noma K, et al. Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment.

show abstract

“…OBP-301 exhibits higher cancer selectivity than standard photosensitizers and only causes sustained tumor accumulation of the KillerRed protein in infected cancer cells [ 140 ]. In mice xenografts, OBP-301 with KillerRed and PDT had higher efficacy against colon cancer lymph node metastasis and orthotopic melanoma [ 141 ]. Similar approaches can be tested and further developed in the treatment of BC.…”

Section: Challenges and Prospectsmentioning

confidence: 99%

Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects

Xia

et al. 2022

JCM

View full text Add to dashboard Cite

Bladder cancer is one of the most prevalent cancers. Despite recent advancements in bladder cancer therapy, new strategies are still required for improving patient outcomes, particularly for those who experienced Bacille Calmette–Guerin failure and those with locally advanced or metastatic bladder cancer. Oncolytic viruses are either naturally occurring or purposefully engineered viruses that have the ability to selectively infect and lyse tumor cells while avoiding harming healthy cells. In light of this, oncolytic viruses serve as a novel and promising immunotherapeutic strategy for bladder cancer. A wide diversity of viruses, including adenoviruses, herpes simplex virus, coxsackievirus, Newcastle disease virus, vesicular stomatitis virus, alphavirus, and vaccinia virus, have been studied in many preclinical and clinical studies for their potential as oncolytic agents for bladder cancer. This review aims to provide an overview of the advances in oncolytic viruses for the treatment of bladder cancer and highlights the challenges and research directions for the future.

show abstract

Eradication of melanoma in vitro and in vivo via targeting with a Killer-Red-containing telomerase-dependent adenovirus

Cited by 9 publications

References 33 publications

Advances in the Genetically Engineered KillerRed for Photodynamic Therapy Applications

Advances in the Genetically Engineered KillerRed for Photodynamic Therapy Applications

Tumor‐targeted fluorescence labeling systems for cancer diagnosis and treatment

Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects

Contact Info

Product

Resources

About